Know Cancer

or
forgot password

The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute


N/A
18 Years
N/A
Not Enrolling
Both
Medication Reconciliation

Thank you

Trial Information

The Impact of Pharmacist Discharge Medication Reconciliation on Unintentional Medication Discrepancies From Inpatient Discharges at the Alberta Cancer Board Cross Cancer Institute


Inclusion Criteria:



- Cancer inpatients under the care of Dr. Follett or Dr. Candler

- Cancer inpatients to be discharged from the CCI

- Patients >18 years of age

- Patients that are taking >1 medications or herbals total at home.

Exclusion Criteria:

- Cancer inpatients that are considered radioactive or in "hot rooms" (ie. Selectron
patients or patients receiving radiation treatment for thyroid)

- Patients that do not remain in hospital >72 hours

- Patients without a home phone number or equivalent contact number.

- Language barrier (patients unable to speak or understand English).

- Patients that are readmitted and already included into the study.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MRS Correlation with Treatment Response.

Outcome Description:

The percentage of patients with at least one unintentional medication discrepancy after discharge from the Cross Cancer Institute

Outcome Time Frame:

up to 1 year

Principal Investigator

Carole Chambers, BSc. Pharmacy

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Health Services

Authority:

Canada: Health Canada

Study ID:

23851

NCT ID:

NCT01226589

Start Date:

October 2007

Completion Date:

October 2008

Related Keywords:

  • Medication Reconciliation
  • Cancer cancer
  • MRS
  • Treatment response
  • Histologically confirmed diagnosed Breast cancer.
  • Patient is 18 years or older.
  • Karnofsky performance score is equal to or greater than 70.
  • No previously irradiated or recurrent breast.
  • No contraindication to MRS/MRI.

Name

Location